Roxana A. Radu

Dr. Roxana A. Radu

UCLA Stein Eye Institute, Los Angeles, California, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TLTamara L. Lenis
Tamara L. Lenis
JHJane Hu
Jane Hu
SNSze Yin Ng
Sze Yin Ng
ZJZhichun Jiang
Zhichun Jiang
SSShanta Sarfare
Shanta Sarfare
RRRoxana A. Radu
Roxana A. Radu
Significance: Recessive Stargardt macular degeneration (STGD1) and a subset of cone–rod dystrophies are caused by mutations in the Abca4 gene. The ABCA4 protein is a flippase in photoreceptor cells that helps eliminate retinaldehyde, a toxic photoproduct of vision. Here we found that ABCA4 is additionally present in the retinal pigment epithelium (RPE) of mice at approximately 1% of its abundance in the neural retina. Genetically modified mice that express ABCA4 in RPE but not in photoreceptor cells showed partial rescue of both the lipofuscin accumulation and photoreceptor degeneration observed in Abca4 −/− mice and in STGD1 patients. These observations suggest that ABCA4 in the RPE prevents photoreceptor degeneration in Abca4 −/− mice and possibly in STGD1 patients.

1 May 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RRRoxana A. Radu
Roxana A. Radu
JHJane Hu
Jane Hu
QYQuan Yuan
Quan Yuan
DWDarcy L. Welch
Darcy L. Welch
JMJacob Makshanoff
Jacob Makshanoff
DBDean Bok
Dean Bok
Accumulation of vitamin A-derived lipofuscin fluorophores in the retinal pigment epithelium (RPE) is a pathologic feature of recessive Stargardt macular dystrophy, a blinding disease caused by dysfunction or loss of the ABCA4 transporter in rods and cones. Age-related macular degeneration, a prevalent blinding disease of the elderly, is strongly associated with mutations in the genes for complement regulatory proteins (CRP), causing chronic inflammation of the RPE. Here we explore the possible relationship between lipofuscin accumulation and complement activation in vivo. Using the abca4(-/-) mouse model for recessive Stargardt, we investigated the role of lipofuscin fluorophores (A2E-lipofuscin) on oxidative stress and complement activation. We observed higher expression of oxidative-stress genes and elevated products of lipid peroxidation in eyes from abca4(-/-) versus wild-type mice. We also observed higher levels of complement-activation products in abca4(-/-) RPE cells. Unexpectedly, expression of multiple CRPs, which protect cells from attack by the complement system, were lower in abca4(-/-) versus wild-type RPE. To test whether acute exposure of healthy RPE cells to A2E-lipofuscin affects oxidative stress and expression of CRPs, we fed cultured fetal-derived human RPE cells with rod outer segments from wild-type or abca4(-/-) retinas. In contrast to RPE cells in abca4(-/-) mice, human RPE cells exposed to abca4(-/-) rod outer segments adaptively increased expression of both oxidative-stress and CRP genes. These results suggest that A2E accumulation causes oxidative stress, complement activation, and down-regulation of protective CRP in the Stargardt mouse model. Thus, Stargardt disease and age-related macular degeneration may both be caused by chronic inflammation of the RPE.

15 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CPChendong Pan
Chendong Pan
KBKalpita Banerjee
Kalpita Banerjee
GLGuillermo L. Lehmann
Guillermo L. Lehmann
DADena Almeida
Dena Almeida
KHKatherine A. Hajjar
Katherine A. Hajjar
MNMarcelo Nociari
Marcelo Nociari
Significance: Retinal lipofuscin causes retinal pigment epithelium cell death in Stargardt and potentially dry–Age-Related Macular Degeneration (AMD). The current dogma is that lipofuscin’s cytotoxicity results from the light-triggered decomposition of its lipid-bisretinoids leading to apoptosis. However, antiapoptotic antioxidants or light-blocking lenses are not effective to stop degeneration in Stargardt and most AMD patients. Here, we show that lipofuscin forms aggregates in lysosomes, which trigger lysosomal membrane permeabilization and subsequent atypical necroptosis. We provide evidence that necrosulfonamide, necrostatin-7, and arimoclomol can effectively control this lethal cascade.

27 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TLTamara L. Lenis
Tamara L. Lenis
SSShanta Sarfare
Shanta Sarfare
ZJZhichun Jiang
Zhichun Jiang
MLMarcia B. Lloyd
Marcia B. Lloyd
DBDean Bok
Dean Bok
RRRoxana A. Radu
Roxana A. Radu
Recessive Stargardt macular degeneration (STGD1) is caused by mutations in the gene for the ABCA4 transporter in photoreceptor outer segments. STGD1 patients and Abca4−/− (STGD1) mice exhibit buildup of bisretinoid-containing lipofuscin pigments in the retinal pigment epithelium (RPE), increased oxidative stress, augmented complement activation and slow degeneration of photoreceptors. A reduction in complement negative regulatory proteins (CRPs), possibly owing to bisretinoid accumulation, may be responsible for the increased complement activation seen on the RPE of STGD1 mice. CRPs prevent attack on host cells by the complement system, and complement receptor 1-like protein y (CRRY) is an important CRP in mice. Here we attempted to rescue the phenotype in STGD1 mice by increasing expression of CRRY in the RPE using a gene therapy approach. We injected recombinant adeno-associated virus containing the CRRY coding sequence (AAV-CRRY) into the subretinal space of 4-wk-old Abca4−/− mice. This resulted in sustained, several-fold increased expression of CRRY in the RPE, which significantly reduced the complement factors C3/C3b in the RPE. Unexpectedly, AAV-CRRY–treated STGD1 mice also showed reduced accumulation of bisretinoids compared with sham-injected STGD1 control mice. Furthermore, we observed slower photoreceptor degeneration and increased visual chromophore in 1-y-old AAV-CRRY–treated STGD1 mice. Rescue of the STGD1 phenotype by AAV-CRRY gene therapy suggests that complement attack on the RPE is an important etiologic factor in STGD1. Modulation of the complement system by locally increasing CRP expression using targeted gene therapy represents a potential treatment strategy for STGD1 and other retinopathies associated with complement dysregulation. Significance The complement system, a key component of innate immunity, is necessary to maintain tissue homeostasis. In the eye, the retinal pigment epithelium (RPE) plays a major role in controlling the immune response through expression of various complement negative regulatory proteins (CRPs). Here we identify that inappropriate activation of the complement cascade plays a role in the pathogenesis of recessive Stargardt disease (STGD1). Using the STGD1 mouse model, we show that overexpression of the complement receptor 1-like protein y, a major murine CRP, reduces complement attack on the RPE and rescues both bisretinoid accumulation and photoreceptor degeneration. Our data demonstrate that STGD1 presents with dysregulation of the complement system as also has been proposed for age-related macular degeneration, supporting a common etiologic pathway.

9 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SJSameeha Jilani
Sameeha Jilani
JSJustin D. Saco
Justin D. Saco
EMEdurne Mugarza
Edurne Mugarza
APAleida Pujol-Morcillo
Aleida Pujol-Morcillo
JCJeffrey Chokry
Jeffrey Chokry
CPCristina Puig-Saus
Cristina Puig-Saus
A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying surface proteins highly expressed in tumors but not in normal tissues. Here, we identify Tyrosinase Related Protein 1 (TYRP1) as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes unresponsive to immune checkpoint blockade. TYRP1 is primarily located intracellularly in the melanosomes, with a small fraction being trafficked to the cell surface via vesicular transport. We develop a highly sensitive CAR-T cell therapy that detects surface TYRP1 in tumor cells with high TYRP1 overexpression and presents antitumor activity in vitro and in vivo in murine and patient-derived cutaneous, acral and uveal melanoma models. Furthermore, no systemic or off-tumor severe toxicities are observed in an immunocompetent murine model. The efficacy and safety profile of the TYRP1 CAR-T cell therapy supports the ongoing preparation of a phase I clinical trial.

16 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
MCMayur Choudhary
Mayur Choudhary
EIEbraheim N. Ismail
Ebraheim N. Ismail
PYPei-Li Yao
Pei-Li Yao
FTFaryan Tayyari
Faryan Tayyari
RRRoxana A. Radu
Roxana A. Radu
GMGoldis Malek
Goldis Malek
Effective treatments and animal models for the most prevalent neurodegenerative form of blindness in elderly people, called age-related macular degeneration (AMD), are lacking. Genome-wide association studies have identified lipid metabolism and inflammation as AMD-associated pathogenic pathways. Given liver X receptors (LXRs), encoded by the nuclear receptor subfamily 1 group H members 2 and 3 ( NR1H3 and NR1H2 ), are master regulators of these pathways, herein we investigated the role of LXR in human and mouse eyes as a function of age and disease and tested the therapeutic potential of targeting LXR. We identified immunopositive LXR fragments in human extracellular early dry AMD lesions and a decrease in LXR expression within the retinal pigment epithelium (RPE) as a function of age. Aged mice lacking LXR presented with isoform-dependent ocular pathologies. Specifically, loss of the Nr1h3 isoform resulted in pathobiologies aligned with AMD, supported by compromised visual function, accumulation of native and oxidized lipids in the outer retina, and upregulation of ocular inflammatory cytokines, while absence of Nr1h2 was associated with ocular lipoidal degeneration. LXR activation not only ameliorated lipid accumulation and oxidant-induced injury in RPE cells but also decreased ocular inflammatory markers and lipid deposition in a mouse model, thereby providing translational support for pursuing LXR-active pharmaceuticals as potential therapies for dry AMD.